Evidence map›Paper›PMID 39760807›Full record

ArticleMetabolic brain disease2025

Jaranol alleviates cognitive impairment in db/db mice through the PI3K/AKT pathway.

Ye Qian, Yue Xu, Qiuyu Zhang, Chengyu Huang, Hui Li, Lin Gao, Shidi Wu, Chengyu Qi, Xiangru Wen, Xiaoyan Zhou and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ye Qian *The Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Yue Xu *The Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Qiuyu ZhangThe Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Chengyu HuangThe Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Hui LiThe Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Lin GaoThe Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Shidi WuThe Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Chengyu QiThe Graduate School, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China.
Xiangru WenDepartment of Chemistry, School of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China. wen_xiangru@126.com.
Xiaoyan ZhouXuzhou Engineering Research Center of Medical Genetics and Transformation, Department of Genetics, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. zhouxiaoyan0201@xzhmu.edu.cn.
Changjiang YingXuzhou Engineering Research Center of Medical Genetics and Transformation, Department of Genetics, Xuzhou Medical University, Xuzhou, 221004, Jiangsu, China. ycj321651@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The widely used Radix Astragali (RA) has significant therapeutic effects on cognitive impairment (CI) caused by type 2 diabetes (T2DM). However, the effective active ingredients and the precise mechanism underly RA alleviation of T2DM-induced CI still require further study. In this study, we aim to elucidate whether and how jaranol, a key effective active ingredient in RA, influences CI in db/db mice. We used various online databases and Cytoscape to screen jaranol as the most active ingredient of RA in the treatment of T2DM-induced CI. The fear conditioning experiment, new object recognition (NOR) test, and Morris water maze (MWM) test were conducted to assess the improvement effect of jaranol on CI in diabetic mice. The protein-protein interaction (PPI) network, Cytoscape, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed to identify key genes. The levels of AKT and caspase-3 were determined by Western blotting. The number of surviving hippocampal neurons was verified through Nissl staining. AutoDock was utilized for predicting potential binding sites between jaranol and key genes.As a result, jaranol attenuated CI in db/db mice probably through activation of PI3K-AKT signaling pathway by inhibiting cell apoptosis in hippocampus. Furthermore, A329 near the active site of AKT1 had hydrogen bond with jaranol. In conclusion, we suggest that jaranol may have therapeutic applications in T2DM-induced CI by targeting the PI3K-AKT signaling pathway directly via key sites. Our study provides alternative drugs and potential therapeutic targets for the prevention and treatment of T2DM-induced CI.

Indexed as

Cognitive DysfunctionPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktSignal TransductionAnimalsDiabetes Mellitus, ExperimentalDiabetes Mellitus, Type 2Drugs, Chinese HerbalHippocampusMaleMiceMice, Inbred C57BLProtein Interaction MapsDrugs, Chinese HerbalPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktApoptosisBioinformatics AnalysisCognitive impairmentJaranolPI3K-AKTType 2 diabetes mellitus

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.